Abstract: Methods for increasing the yield of almond trees by the application of certain plant growth regulators are disclosed. In one embodiment, a brassinosteroid is applied to a variety of the species Prunus dulcis in the growth stage two weeks after full bloom. In another embodiment, the almond trees are treated at the time of petal fall with a brassinosteroid during the formation the ovaries and nutlets. Non-brassinosteroid plant growth regulators such as Forchlorfenuron and Gibberellic acid may be applied with a brassinosteroid to further promote growth. The inventors hypothesize that changes in reproductive physiology such as increasing pollen tube growth and pollen germination rates that ultimately result in greater crop yield are promoted by applications of brassinosteroids.

Abstract: Formulations and methods for weight loss and body contouring are disclosed. An illustrative formulation comprises human chorionic gonadotrophin (hCG) and resveratrol. An illustrative method for weight loss and body contouring comprises administering hCG and resveratrol sublingually.

Abstract: The invention relates to a novel combined disinfection and decontamination agent comprising at least one vitamin, at least one metal ion, at least one active-surface compound, and at least one further antimicrobial active substance. The agent according to the invention surprisingly shows nearly complete nucleic acid disintegration in addition to an improved disinfectant effect. The agent can be successfully used as a combined decontamination and disinfection agent for skin, mucous membranes, hands, wounds, and/or hair, and instruments and surfaces of all kinds.

Abstract: A synergistic microbicidal composition containing a phenolic compound selected from the class consisting of chlorinated phenols, monosubstituted phenols, fused bicyclic phenols, isopropyl methyl catechols, and monosubstituted catechols and an antimicrobial alcohol selected from the class of menthadiene alcohols and other antimicrobial alcohols.

Abstract: A synergistic microbicidal composition containing a selected from the class consisting of chlorinated phenols, fused bicyclic phenols, monosubstituted phenols and monosubstituted catechols and an antimicrobial alcohol selected from the class consisting of acyclic terpene alcohols.

Abstract: Provided herein are methods and compositions comprising resorcinol derivatives for the use of treating, regulating or preventing a skin condition characterized by oxidative stress or a degenerative process. Methods of preventing, lightening or reducing the appearance of visible discontinuities of the skin resulting from skin pigmentation, skin aging, or other disorders are also disclosed.

Abstract: Uric acid in mammalian subjects is reduced and excretion of uric acid is increased by administering a compound of Formula I or a pharmaceutically acceptable salt thereof. In Formula I m is 0, 1, 2, 3 or 4; n is 0 or 1; t is 0 or 1; q is 0 or 1; and r is 0, 1 or 2. R6 is hydrogen, O or hydroxyl. R7 is hydrogen or alkyl having from 1 to 3 carbon atoms. One of R8 and R9 is alkyl having from 1 to 3 carbon atoms, and the other is hydrogen or alkyl having from 1 to 3 carbon atoms. R10 is hydrogen, halo, alkyl having from 1 to 3 carbon atoms or alkoxy having from 1 to 3 carbon atoms. X is C(O) and r is 0 and t is 0; or X is NH(R11) wherein R11 is hydrogen or alkyl having from 1 to 3 carbon atoms.

Abstract: The invention relates to the use of cannabidiol (CBD), at a dose of greater than 300 mg/day, in combination with a standard anti-epileptic drug (SAED) which acts via sodium or calcium channels, for use in the treatment of epilepsy. The SAED is preferably one which•modifies low-threshold or transient neuronal calcium currents,or•reduces high-frequency neuronal firing and sodium-dependent action potentials and enhances GABA effects. Preferred SAEDs are ethosuximide and valproate.

Abstract: The invention encompasses pharmaceutical formulations for the prevention and treatment of Wolbachia-related disease wherein the formulations comprise a compound previously unknown and unused for such a purpose, the compound being one or more of: Pararosaniline Pamoate, Pyrvinium Pamoate, Clofoctol, and Isoreserpine, derivatives, metabolites, precursors, pro-drugs and variants thereof.

Abstract: The invention relates to the use of cannabidiol (CBD), at a dose of greater than 300 mg/day, in combination with a standard anti-epileptic drug (SAED) which acts via sodium or calcium channels, for use in the treatment of epilepsy. The SAED is preferably one which•modifies low-threshold or transient neuronal calcium currents,or•reduces high-frequency neuronal firing and sodium-dependent action potentials and enhances GABA effects. Preferred SAEDs are ethosuximide and valproate.

Abstract: The present invention provides an antibacterial oral rinse formulation having enhanced antibacterial activity against oral bacteria associated with infectious and inflammatory processes for preventing and/or treating inflammatory diseases or inflammatory processes associated with diseases in an individual by inhibiting the transient bacteremia associated with oral hygiene activities by the individual. Also provided is a method for preventing and/or treating inflammatory diseases or inflammatory processes associated with diseases in an individual by inhibiting transient bacteremia associated with oral hygiene activities by the individual, comprising rinsing with the antibacterial oral rinse formulation for a period of time immediately prior to engaging in oral hygiene activities.

Abstract: Pharmaceutical compositions of 4-hydroxy tamoxifen, particularly compositions suitable for percutaneous administration, are useful in methods for treating and preventing breast cancer. When percutaneously administered to a patient's breasts, 4-hydroxy tamoxifen concentrates locally, and exerts an anti-estrogenic effect. In patients with breast cancer, this effect reduces tumor tissue proliferation. In patients at risk for developing breast cancer, the anti-estrogenic effect prevents breast tumor formation.

Abstract: A synergistic antimicrobial composition. The composition contains at least two components. The first component is ortho-phenylphenol or its alkali metal or ammonium salts. The second component is 4,4-dimethyloxazolidine (DMOZ).

Abstract: A dietary supplement composition is provided for enhancing the expression of a sirtuin gene or protein. An inventive supplement composition includes at least one cinnamon extract containing at least 0.5% doubly linked Type-A polymers by dry weight. The cinnamon extract is derived from the Cinnamonum aromaticum, Cinnamonum verum or Cinnamonum burmannii plant. In some embodiments, the cinnamon extract is present at approximately 20%-50% of the dry weight of the composition. A vitamin, weight loss agent, or antioxidant is optionally provided in the composition. The dietary supplement composition is administered orally to promote expression or enhanced expression of a sirtuin gene or protein.

Abstract: Wallboard and facing paper that provides increased mold resistance at lower biocide loadings. The biocide is: (a) an n-alkyl isothiazolinone such as octylisothiazolinone (OIT), a monohalo and dihalo substituted n-alkylisothiazolinone such as chloromethylisothiazolinone (CMIT) or dichlorooctylisothiazolinone (DCOIT), 3-iodo-2-propynyl-butylcarbamate (IPBC), chlorothalonil, methylene-bis-thiocyanate, or mixtures of two or more thereof; or (b) carbendazim and a second biocide selected from 3-iodo-2-propynyl-butylcarbamate (IPBC), diiodomethyltolylsulfone (DIMTS), sodium pyrithione, octylisothiazolinone (OIT), dichlorooctylisothiazolinone (DCOIT), and chlorothalonil.

Abstract: A (?)-stereoisomer of formula (I): (formula I), wherein X is H or F; or a pharmaceutically acceptable salt or pro drug thereof, is useful as an anesthetic.

Abstract: A composition for counteracting malodour due to thiols, with the composition including a polyphenol, a source of polyphenol, a composition comprising polyphenol or mixtures thereof, a base, and optionally, an enzyme, wherein the polyphenol is encapsulated. The polyhenol is preferably a green tea extract and the enzyme is polyphenol (per)oxidase acetone powder.

Abstract: The present invention is a novel analgesic combination and its use. It is classified to be an invention in the field of medicine and technology. The purpose of this invention is to solve the problem that existing analgesics does not effectively attenuate pain or produces serious side-effects in clinic. The ingredients of the analgesic combination include ketanserin and propranolol. This combination is used to make a drug to treat pain. Because the ingredients of the analgesic combination target peripheral receptors, the unwanted effects could be only minimal. The big advantage of this combination is that each of the ingredients acts on the different receptors producing the synergizing analgesic. Therefore, the analgesia that the combination produces is remarkable and the effective doses are low.

Abstract: A paper product having an antimicrobial composition dispersed with the substrate is provided. In particular, a paper towel such as those found in public washrooms or institutions comprises an antimicrobial composition. The substrate can also be a facial tissue, kitchen towel, serviette or any type of personal hygiene product. The antimicrobial composition preferably comprises a phenol-derived antimicrobial agent. The paper products of the present invention appear dry to the touch.

Abstract: The present invention relates to a formulation comprising (a) at least one pesticide; and (b) at least one non-ionic surfactant of formula (I): R1—O-(AO)x—(H); wherein R1 represents straight-chain or branched alkyl having 4 to 20 carbon atoms; AO is ethyleneoxy, propyleneoxy or a mixture of ethyleneoxy and propyleneoxy; and x correspond to values from 2 to 30; and (c) at least one ionic tristyrylphenyl alkoylate; and (d) at least one oil; and (e) water, wherein the pesticide is present in the aqueous phase in form of a suspension and the oil is essentially free of pesticide.

Abstract: The invention relates to a novel combined disinfection and decontamination agent comprising at least one vitamin, at least one metal ion, at least one active-surface compound, and at least one further antimicrobial active substance. The agent according to the invention surprisingly shows nearly complete nucleic acid disintegration in addition to an improved disinfectant effect. The agent can be successfully used as a combined decontamination and disinfection agent for skin, mucous membranes, hands, wounds, and/or hair, and instruments and surfaces of all kinds.

Abstract: In one aspect, the invention relates to a method for identifying a drug candidate with activity as a neuroprotective agent. The method includes determining whether a compound reduces ATF4 activity; and identifying the compound that reduces ATF4 activity as a drug candidate.

Abstract: The invention provides antiseptic compositions that comprise a wide spectrum antiseptic component (WSAC) and optionally one or more other active ingredients. The WSAC comprises an alcohol, one or more antimicrobial phenol compounds, one or more antimicrobial agents, a solvent and optionally, one or more non-ionic detergents. Additional components such as additional active agents, and thickeners can also be optionally added. The antiseptic compositions have a wide-spectrum of antiseptic activity against microorganisms and exhibit minimal toxicity and minimal irritation and can be used to treat and/or prevent dermal, mucosal, cuticle (such as nail or hoof) or genital infections in a patient.

Abstract: Composition for application to skin comprising a biocide or combination of biocides (such as chlorhexidine, halogenated phenols, quaternary ammonium compounds; povidone-iodine; zinc pyridinethione; alcohols etc.) and at least one transcutaneous vehicle (for example alkyl methyl sulfoxides, alkyl pyrrolidones, glycols, glycol ethers and glycol esters) effective to convey the biocide to a sub epidermal “resident” micro-organism. Also a method for preparing a patient for surgery comprising the step of treating an area of the patient's skin at, and in the surrounding the vicinity of, the site of an intended surgical incision with a composition effective to kill more than 93% of both “transient” and “resident” micro-organisms.

Abstract: The invention provides methods and kits for screening a test agent for antiviral activity against Norovirus. The methods are effective in terms of determining the amount of intact Norovirus while decreasing the amount of interfering RNA and PCR inhibitors within the test sample.

Abstract: The present invention relates to a composition comprising an NF?B-inhibitor and a non-retinoid collagen promoter.

Abstract: Articles having metallic finishes including antimicrobial agents dispersed throughout the finish and methods of electroplating said metallic finishes on a material. The metallic finishes include highly-decorative electroplated finishes for bathroom and kitchen hardware, door hardware, and other highly lustrous products where antimicrobial protection is preferred.

Abstract: An antimicrobial coating composition consisting essentially of 70 to 80 wt. percent water; 5 to 10 wt. percent methyl alcohol; 3 to 8 wt. percent octadecyl dimethyl trimethoxy silylpropyl-ammonium chloride; 1 to 5 wt. percent chloropropyl trimethoxysilane; 0.5 to 1.5 wt. percent aminopropyltrialkoxysilane; 0.5 to 1.5 wt. percent of a surfactant; 1 to 1.5 wt. percent of an anti-microbial agent; and 0.5 to 2.5 wt. percent sulfuric acid.

Abstract: The present invention provides RecA inhibitors, compositions containing them, systems for identifying or characterizing them, and methods of using them.

Abstract: A blood pressure measurement cuff comprising an inflatable bladder, a source of fluidic pressure in fluidic communication with the inflatable bladder, a manometer in fluidic communication with the inflatable bladder, a cover at least partially covering the inflatable bladder and comprising an antimicrobial substance, and means to place the inflatable bladder sufficiently close to a limb of a living being to allow the measurement of the blood pressure of the living being. The source of fluidic pressure can be a pump that transforms human force into fluid pressure, such as a squeezable ball pump, or a canister of compressed fluid. The manometer can include a dial display or a digital display. The cuff can further comprise a tube providing fluidic communication between the manometer and the inflatable bladder, and the tube can be 1 foot or longer. The cover can be made of a fabric coated with an antimicrobial substance.

Abstract: Methods for diagnosing a pelvic pain disorder that include analyzing samples for increased levels and/or nuclear accumulation of beta-catenin, which indicates presence of the pelvic pain disorder, particularly interstitial cystitis. Therapeutic treatment of a pelvic pain disorder, particularly interstitial cystitis, includes the administration to a patient of an effective amount of an inhibitor of beta-catenin activity. This can be carried out by direct administration of the therapeutic agent or via gene therapy.

Abstract: Provided are methods, test devices, and diagnostic kits for predicting, assessing, and diagnosing the risk of a disease using salivary analysis. The methods comprise providing a whole (unfractionated) saliva sample from a subject; contacting an aliquot of the saliva with two or more lectins under conditions that allow the two or more lectins to bind to a lectin-binding component of the saliva; detecting the amount of bound lectin; and comparing the amount of bound lectin to the amount known to bind a saliva sample from a control patient, to predict the risk of a disease in the subject. Also provided are methods for reducing the risk of a disease and a method for assessing the risk of the disease at a defined level.

Abstract: The present invention provides novel 2,6-diisopropyl phenol 2,6-diisopropyl phenol analogs and sterile, stable pharmaceutical compositions of 2,6-diisopropyl phenol 2,6-diisopropyl phenol and analogs thereof useful as an antioxidant in the treatment of ischemic injury including stroke and other cerebral injury. 2,6-diisopropyl phenol or its analogs are administered in a dosage effective to produce blood levels and brain levels of the drug that can prevent free radical damage associated with ischemic injury.

Abstract: Wiring devices that are manufactured by incorporating antimicrobial agents therein help eliminate or reduce any microorganisms that are present on the surface of the wiring device, and thus help prevent the spread of infection and disease from one person to another. By incorporating the antimicrobial agent into a resin mixture used for making wiring devices, the antimicrobial agent continues to leach out to the surface of the wiring device over time, resulting in a more effective, longer-lasting option than conventional cleaners. Methods of fabricating the wiring devices to include antimicrobial agents includes adding a prescribed amount of antimicrobial agent to a base material, mixing the agent and material to create a mixture, and extruding the mixture into one or more molds to form a wiring device of desired configuration.

Abstract: Pharmaceutical compositions of 4-hydroxy tamoxifen, particularly compositions suitable for percutaneous administration, are useful in methods for treating and preventing breast cancer. When percutaneously administered to a patient's breasts, 4-hydroxy tamoxifen concentrates locally, and exerts an anti-estrogenic effect. In patients with breast cancer, this effect reduces tumor tissue proliferation. In patients at risk for developing breast cancer, the anti-estrogenic effect prevents breast tumor formation.

Abstract: The present invention provides a pharmaceutical composition comprising a combination of an Hsp 90 family protein inhibitor and at least one compound, the said pharmaceutical composition wherein the Hsp 90 family protein inhibitor is a benozoyl compound represented by formula (I): [wherein n represents an integer of 1 to 5; R1 represents substituted or unsubstituted lower alkyl, CONR7R8 (wherein R7 and R8, which may be the same or different, each represent a hydrogen atom, substituted or unsubstituted lower alkyl, or the like), or the like; R2 represents substituted or unsubstituted aryl, or the like; R3 and R5, which may be the same or different, each represent a hydrogen atom, substituted or unsubstituted lower alkyl, or the like; R4 represents a hydrogen atom, hydroxy or halogen; and R6 represents a hydrogen atom, halogen, substituted or unsubstituted lower alkyl, or the like], or a prodrug thereof; or a pharmaceutically acceptable salt thereof, and the like.

Abstract: Novel vitamin D analogs, markedly active in the fields of cell proliferation and differentiation, are selected from among (4E,6E)-7-{3-[2-(3,4-bis-hydroxymethylphenyl)-ethyl]phenyl}-3-ethylnona-4,6-dien-3-ol, (E)-6-[3-(3,4-bis-hydroxymethylbenzyloxy)phenyl]1,1,1-trifluoro-2-trifluoromethyloct-5-en-3-yn-2-ol, (3E,5E)-6-[3-(3,4-bis-hydroxymethylbenzyloxy)-phenyl]-1,1,1-trifluoro-2-trifluoromethylocta-3,5-dien-2-ol, (E)-6-{3-[2-(3,4-bis-hydroxymethylphenyl)ethyl]phenyl}-1,1,1-trifluoro-2-trifluoromethyloct-5-en-3-yn-2-ol, and (3E,5E)-6-{3-[2-(3,4-bis-hydroxymethylphenyl)-ethyl]phenyl-1,1,1-trifluoro-2-trifluoromethylocta-3,5-dien-2-ol, and the geometric isomers thereof and these compounds in which one or more of the hydroxyl functions are protected by a protective group —(C?O)—R, in which R is a linear or branched alkyl radical having from 1 to 6 carbon atoms, an aryl radical having from 6 to 10 carbon atoms, or an aralkyl radical having from 7 to 11 carbon atoms, the aryl radical or the aralkyl radical optional

Abstract: A formulation and method for delivery of bioactive substances when applied to, or within, the skin or other exterior region of a mammal. for example, a patient, includes a vasoactive agent; an osmolyte; and an active ingredient. The formulation is sufficiently hygroscopic so as to create a condition of hypertonicity when absorbed by the skin. When the formulation is applied to the skin, the vasoactive agent can be delivered to the dermis so as to contact the vasculature of a patient.

Abstract: The present invention relates to a compound of general formula (I) below in which R1, R2 and R3 represent, independently of one another, a hydrogen atom or a C1-C6 alkyl group or a (C1-C6 alkyl)carbonyl group, R4, R5, R6 and R7 represent a hydrogen or a C1-C6 alkyl group, a C1-C6 alkoxy group or a (C1-C6 alkyl)carbonyloxy group, and n is an integer between 8 and 20, or its pharmaceutically acceptable addition salts, isomers, enantiomers and diastereoisomers, and also mixtures thereof. The invention also relates to a pharmaceutical composition comprising the compound and to the use thereof as a neurotrophic agent.

Abstract: Methods of treating or preventing axonal degradation in neuropathic diseases and neurological disorders in mammals are disclosed. The methods can comprise administering to the mammal an effective amount of an agent that acts at least in part by increasing sirtuinAMPK activity, LKB 1 activity and/or CaMKK? activity in diseased and/or injured neurons. The methods can also comprise administering to the mammal an effective amount of an agent that acts by increasing NAD activity in diseased and/or injured neurons, alone or in combination with agents that act by other mechanisms. Also disclosed are methods of screening agents for treating a neuropathies and recombinant vectors for treating or preventing such neuropathies.

Abstract: The present invention relates to specific (cosmetic) formulations for improving the bioavailability and activity of skin- or hair-lightening or senile keratosis-reducing diphenylmethane derivatives (tyrosinase inhibitors) of the following formula 1:

Abstract: Methods of using absorption enhancer as a component of skin care compositions for moisturizing and protecting the skin. Antimicrobial skin care compositions for cleansing and moisturizing the skin, comprising an absorption enhancer, an antimicrobial function enhancer and bound lipid removals, humectants, emollients and extracts of botanical herbs. Methods for preparing skin care compositions comprising an absorption enhancer.

Abstract: The present invention provides a therapeutic agent for a tumor selected from a hematopoietic tumor and a solid tumor which comprises, as an active ingredient, a benzoyl compound represented by General Formula (I): (wherein n represents an integer of 1 to 5; R1 represents substituted or unsubstituted lower alkoxy, substituted or unsubstituted lower alkoxycarbonyl, CONR7R8 or the like; R2 represents substituted or unsubstituted aryl or a substituted or unsubstituted aromatic heterocyclic group; R3 and R5 may be the same or different, and each represents a hydrogen atom, substituted or unsubstituted lower alkyl or the like; R4 represents a hydrogen atom, hydroxy or halogen; and R6 represents a hydrogen atom, halogen, substituted or unsubstituted lower alkyl or the like), a prodrug thereof or a pharmaceutically acceptable salt thereof.

Abstract: The present invention relates to the use of compounds of the formula (1) wherein all substitutents have the meanings as defined in claim 1 as preservatives in personal care, pharmaceutical and household; the preservatives can also be used as in-can preservatives.

Abstract: An emulsion cosmetic composition comprising at least one resveratrol derivative, an aqueous phase, and an oil phase having at and at least one oil phase structuring agent, and a method for preparing emulsions capable of delivering active resveratrol to the skin.

Abstract: The present invention includes compositions and methods treat a patient suffering from one or more symptoms of cardiac hypertrophy, hypertension and/or ischemia by administering a pharmaceutically effective amount of a pharmaceutical composition having an anti-epileptic drug and an antibiotic to the patient, for example, the anti-epileptic drug may be carbamazepine and the antibiotic may be doxycycline.

Abstract: Disclosed are anti-viral compositions containing at least one zinc compound and at least one phenolic antioxidant (and optionally other ingredients), and a pharmaceutical carrier. Also disclosed are methods of treating lesionous symptoms of a viral infection involving applying an effective amount of the anti-viral composition to the lesions.

Abstract: The invention provides extracts of brown seaweed of the genus Ascophyllum that have valuable pharmacological properties. In particular, compositions of the invention are useful for e.g.: inhibiting alpha-glucosidase activity; preventing or treating conditions mediated by alpha-glucosidase activity; reducing blood glucose levels; preventing or treating diabetes; modulating glucose uptake in adipocytes; preventing or treating obesity; scavenging free radicals; stimulating the immune system; activating macrophages; preventing or treating condition mediated by macrophage activation; and modulating nitric oxide production by macrophages. Methods for using the Ascophyllum extracts of the invention are provided, as are kits comprising Ascophyllum extracts of the invention and instructions for using the extracts.

Abstract: The present invention comprises an antimicrobial composition. More particularly to an antimicrobial composition that comprises a. from about 0.01% to about 15% of at least one non-anionic surfactant, by weight of the composition; b. from about 0.01% to about 15% of at least one acid, by weight of the composition; c. from about 0% to about 99.85% of water, by weight of the composition; and wherein the composition is foaming.

Abstract: The present invention relates to a compound of formula I, or a pharmaceutically acceptable salt thereof. Formula (I), wherein R1 and R2 are each independently H or alkyl; Y is an alkyl group. CONR3R4, COOR5SO2NR16R17, NHSO2R18 or CN; X is an aryl or heteroaryl group, each of which may be optionally substituted with one or more substituents selected from (CH2)mZ where Z is halogen, OH, CN, alkyl, alkoxy, NO2, CF3, CONR6R7, CN, NR8R9, COOR10 or NHCOR11 and m is 0 to 3; R3 to R11 are each independently H, alkyl or aryl, wherein said alkyl and aryl groups are optionally substituted by one or more substituents selected from halogen, OH, CN, alkyl, alkoxy, NO2, CF3, CONR12R13, CN, NH2, COOR14, NHCOR15, and CN; R12 to R18 are each independently H or alkyl, more preferably H or Me; n is 1 to 6; wherein the compound is other than 3?,5?-dimethyl-4-(1,1-dimethylheptyl)-1,1?-biphenyl-2-ol.